JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 180 filers reported holding JUNO THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.57 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,830,000 | +4.4% | 61,919 | +2.5% | 0.01% | 0.0% |
| Q3 2017 | $2,711,000 | +52.0% | 60,426 | +1.3% | 0.01% | +50.0% |
| Q2 2017 | $1,783,000 | +15.6% | 59,642 | -14.2% | 0.00% | 0.0% |
| Q1 2017 | $1,542,000 | +24.7% | 69,486 | +5.9% | 0.00% | +33.3% |
| Q4 2016 | $1,237,000 | -31.1% | 65,633 | +9.7% | 0.00% | -40.0% |
| Q3 2016 | $1,795,000 | -15.6% | 59,813 | +8.1% | 0.01% | -16.7% |
| Q2 2016 | $2,128,000 | +421.6% | 55,351 | +417.1% | 0.01% | +500.0% |
| Q1 2016 | $408,000 | -15.4% | 10,704 | -2.3% | 0.00% | -50.0% |
| Q4 2015 | $482,000 | +13.9% | 10,954 | +5.5% | 0.00% | +100.0% |
| Q3 2015 | $423,000 | -18.7% | 10,384 | +6.5% | 0.00% | -50.0% |
| Q2 2015 | $520,000 | – | 9,747 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |